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Wild-type and variant forms of transthyretin (TTR), a normal plasma
protein, are amyloidogenic and can be deposited in the tissues as amyloid
fibrils causing acquired and hereditary systemic TTR amyloidosis, a debili-
tating and usually fatal disease. Reduction in the abundance of amyloid
fibril precursor proteins arrests amyloid deposition and halts disease
progression in all forms of amyloidosis including TTR type. Our previous
demonstration that circulating serum amyloid P component (SAP) is effi-
ciently depleted by administration of a specific small molecule ligand
compound, that non-covalently crosslinks pairs of SAP molecules, suggested
that TTR may be also amenable to this approach. We first confirmed that
chemically crosslinked human TTR is rapidly cleared from the circulation
in mice. In order to crosslink pairs of TTR molecules, promote their acceler-
ated clearance and thus therapeutically deplete plasma TTR, we prepared a
range of bivalent specific ligands for the thyroxine binding sites of TTR.
Non-covalently bound human TTR–ligand complexes were formed that
were stable in vitro and in vivo, but they were not cleared from the plasma
of mice in vivo more rapidly than native uncomplexed TTR. Therapeutic
depletion of circulating TTR will require additional mechanisms.1. Background
Systemic amyloidosis is a serious disease caused by the extracellular deposition
of circulating globular proteins as abnormal, insoluble fibrils in the viscera,
blood vessel walls and connective tissues. It is usually fatal, causing about
one per thousand deaths in developed countries [1]. Wild-type transthyretin
(TTR) is a normal plasma protein that circulates as a tetramer of four identical
subunits and acts as a transporter for thyroid hormone and retinol binding
protein. It is inherently amyloidogenic and forms microscopic amyloid deposits
in almost all individuals aged over 80 years [2]. Massive deposits in the heart
can also occur, causing fatal senile cardiac TTR amyloidosis [3]. The inherent
amyloidogenicity of wild-type TTR is markedly enhanced by most of the
reported more than 100 different point mutations that encode single residue
substitutions in the TTR sequence. These mutations cause autosomal dominant
adult-onset hereditary amyloidosis, a universally fatal condition affecting about
10 000 patients worldwide. The usual clinical presentation is familial amyloid
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Figure 1. Bifunctional ligands for crosslinking TTR tetramers based on the
dichlorophenylaminobenzoic acid head group with either polyproline
(group I) or polypiperidine (group II) linkers. Ligand IIe has a modified
ether linkage in place of the aminopropoxy linkage.
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neuropathy, but there is commonly also serious involvement
of the heart, kidneys and eyes. The condition typically presents
after the causative gene has been transmitted to the proband’s
offspring, ensuring persistence of this devastating disease.
Amyloidogenic mutations occur in all ethnic groups, but by
far the most common, Val30Met, clusters in three geographical
foci: Northern Portugal, Northern Sweden and parts of Japan.
A common amyloidogenic variant in the UK and Eire is
Thr60Ala. TTR amyloidosis predominantly affecting the heart
is particularly associated with the Val122Ile variant, which is
very rare in Caucasians but is carried by 4% of African-
Americans [4]. It is the second most common pathogenic
mutation in that population after sickle cell haemoglobin.
Cardiac TTR amyloidosis presents as progressive, ultimately
fatal, heart failure owing to restrictive cardiomyopathy, is
rarely suspected and is usually misdiagnosed as coronary
heart disease.
There was no effective treatment for TTR amyloidosis
until orthotopic liver transplantation was introduced in 1991
[5]. Circulating TTR is synthesized mainly by hepatocytes,
and liver transplantation removes the source of the amyloido-
genic variant TTR in the plasma and replaces it with wild-
type TTR. However, the procedure is available for only a
minority of patients and optimal results are obtained early in
the disease. Furthermore, patients with mutations other than
Val30Met have developed rapidly progressive cardiac amyl-
oidosis after transplantation [6], presumably because of the
natural amyloidogenicity of wild-type TTR. In patients
with predominant cardiac amyloid, heart transplantation is a
possible option, but most are too old and are not acceptable
recipients of scarce donor organs. Nevertheless, the efficacy
of liver transplantation in arresting amyloid deposition
for patients with the Val30Met mutation demonstrated the
potential efficacy of plasma TTR depletion as a treatment for
TTR amyloidosis.
One approach to TTR depletion is direct inhibition of
hepatic synthesis, and this has lately been successfully
demonstrated by ISIS Pharmaceuticals, Inc. [7] and by
Alnylam Pharmaceuticals [8] using pharmaceutical anti-
sense oligonucleotide and siRNA approaches, respectively.
Alternatively, the concentration of circulating TTR could be
lowered by increasing its clearance. Native TTR is mainly
catabolized in the liver, but also in muscle, skin, kidney,
adipose tissue and the gastrointestinal tract [9]. Fibroblasts
have recently been shown to remove TTR aggregates [10].
Disruption and clearance of TTR amyloid deposits is also a
potential therapeutic approach [11]; however, prevention of
amyloid deposition would be preferable. We therefore
sought tomodify the native structure of circulating TTR to pro-
mote its accelerated clearance from the plasma and catabolism
leading to TTR depletion. We have previously shown that
clearance of human serum amyloid P component (SAP) is dra-
matically increased by non-covalently crosslinking pairs of
SAPmolecules with a palindromic bifunctional small molecule
ligand, hexanoyl bis(D-proline) (CPHPC), that is specifically
bound by SAP [12]. Plasma SAP remains at extremely low con-
centration for as long as the drug is administered [13]. We
therefore designed a range of bifunctional ligands to be specifi-
cally and non-covalently bound by human TTR, crosslinking
pairs of the native protein molecules in stable complexes that,
similarly to the SAP–CPHPC complexes, would, we hoped,
be recognized as abnormal and promptly cleared.2. Material and methods
Isolated human TTR was purchased from Scipac Ltd, Kent,
UK and dissolved in phosphate-buffered saline (PBS).
Sodium [125I] iodide and 125I-thyroxine were purchased from
Perkin Elmer, Seer Green, UK. TTR was radiolabelled with
125I using N-bromosuccinimide and sodium [125I] iodide in
PBS for 10–15 s and purified on a PD10 desalting column
(Bio-Rad, Hemel Hempstead, UK) [14]; 125I-TTR was mixed
with native TTR as a marker for in vivo clearance experiments.
Chemically crosslinked TTR was generated by treatment of
TTR (10 mgml21)with a 50-foldmolar excess ofN-(3-dimethyl-
aminopropyl)-N’-ethylcarbodiimide hydrochloride (EDC,
Sigma-Aldrich, Gillingham, Dorset, UK) in water at pH 5.
Two sets of bivalent potential TTR crosslinking ligands
were prepared by coupling two molecules of the head
group 2-(3,5-dichlorophenylamino)-5-methoxy-benzoic acid
with either polyproline (group I) or polypiperidine (group II)
linkers. The structures of the ligands are shown in figure 1.
The head group and group II ligands were synthesized
by Selcia Ltd, Ongar, Essex, UK; full details are in
the electronic supplementary material. The group I peptide
succinimido-(Pro)n-Gly-OH (n ¼ 5–10) ligands were pre-
pared by Peptide Protein Research Ltd, Southampton, UK
using Fmoc peptide chemistry on a Symphony automated
peptide synthesizer (Protein Technologies, Manchester, UK).
The peptides were cleaved from the solid support and puri-
fied by RP-HPLC. The methyl ester protected and amino
functionalized 5-amino-2-(3,5-dichlorophenylamino)benzoic
acid head group (supplied by Selcia Ltd) was reacted to
each peptide using a 2.5-fold molar excess of head group,
and monitored by mass spectrometry for addition of head
group to both ends of the peptide. The crude product was
lyophilized and the methyl ester saponified by the addition
of lithium hydroxide in methanol/water. The polyproline
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Figure 2. (a) A280 UV absorbance gel filtration profiles of native TTR (dotted
line) and EDC crosslinked TTR (E-TTR, solid line). Native untreated TTR chromato-
graphs as a tetramer on gel filtration eluting at 14.2 ml while EDC crosslinked
TTR elutes mainly as high molecular weight oligomers (Ve 7.5 9.0 ml). Both
native TTR (T) and EDC-treated TTR (E-TTR) can bind 125I-thyroxine as shown
in the native gel autoradiogram (inset). Native TTR migrates towards the
anode while EDC-TTR remains mostly at the site of sample deposition (arrowed).
As some of the aggregates may have reduced thyroxine-binding capacity, the
relative intensities in the autoradiogram may not reflect the absolute amounts
of material present on the gel. The gel filtration A280 UV absorbance profile gives
a more accurate representation of relative amounts. (b) Clearance of EDC-treated
125I-TTR (closed circles) in wild-type mice is faster than for TTR control (open
circles); data are expressed as mean and s.d. (n ¼ 3). (c) 125I-TTR is localized
in the spleen of animals treated with oligomerized EDC-TTR. Kid, kidney; spl,
spleen; liv, liver.
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Further details of synthesis and purification methods are avail-
able in the electronic supplementary material. Ligands were
dissolved in DMSO at a concentration of 5–10 mM and stored
at 2308C until used. For binding experiments, TTR was used
at a concentration of 200 mg ml21 (3.6 mM tetramer) in PBS,
which iswithin the normal range of circulating TTR.All ligands
were examined using a TTR/125I-thyroxine displacement assay
as previously described [15,16]. TTR/ligand complexes were
prepared by incubation of TTR (1 mg ml21 in PBS) with a
0- to fivefold molar excess of ligand for up to 18 h at room
temperature. The concentration of DMSO was kept below
2%. Complexes were gel filtered at 0.5 ml min21 on a Superdex
200 column in either PBS or 150 mM ammonium bicarbonate
(pH 7.6) using an Akta Explorer (GE Healthcare, Amersham,
Bucks, UK). Molecular weight markers used to calibrate
the column were: ribonuclease A (13 700) 18.7 ml, carbonic
anhydrase (29 000) 15.8 ml, conalbumin (75 000) 13.7 ml,
ferritin (440 000) 9.8 ml and blue dextran (2 000 000) 8.2 ml.
Binding of 125I-thyroxine by TTR oligomers was examined
by native gel electrophoresis in 1% agarose gel in barbitone–
calcium buffer (180 V, 1 h) [17] followed by autoradiographic
analysis (Typhoon scanner, GE Healthcare). Analytical ultra-
centrifugation was carried out in the An-50 Ti rotor (XL-I
ultracentrifuge, Beckman-Coulter).
TTR/ligand complexes were analysed by nanoflow elec-
trospray mass spectrometry. Mass spectra were recorded
(LCT mass spectrometer with Z-spray source; Waters, Elstree,
Herts, UK) with capillary voltage of 1.7 kV, sample cone at
80 V, extraction cone at 5 V, ion transfer stage pressure at
5.50 millibar, and time of flight analyser pressure at 1.75 
1026 millibar. For ligand dissociation experiments, the
sample cone voltage was increased stepwise to 200 V.
Tandem MS was carried out on a QSTAR XL platform
(MDS Sciex) with capillary voltage of 1.4 kV, declustering
potential at 100 V, focusing potential at 150 V and collision
energy up to 120 V. The relevant m/z range was selected in
the second quadrupole and subjected to acceleration in the
collision cell. Immediately before analysis, fully reduced
recombinant 15N-labelled TTR [18] preparations were
buffer-exchanged into 20 mM ammonium acetate, pH 7.0
(Micro Bio-Spin 6 column; Bio-Rad). TTR (4.4 mM) in the
presence of different molar ratios of ligands or DMSO alone
(2.5% v/v final DMSO concentration) were used to monitor
ligand binding and formation of TTR oligomers. All spectra
were calibrated externally using CsI and processed with
MASSLYNX v. 4.0 (Waters).
In vivo clearance of EDC-TTR was measured in wild-type
C57BL/6 mice. Clearance of the non-covalent TTR–ligand
complexes was determined in TTR-knockout C57BL/6.SPF
congenic mice [19] to avoid any possible ligand exchange
between mouse and human TTR. Preformed complexes in
PBS were injected intravenously into the tail vein and blood
samples collected into heparin at 5, 30, 60 and 180 min.
Plasma TTR was quantified by electroimmunoassay in 1%
w/v agarose gels prepared in barbitone–EDTA buffer pH
8.6 [20] using monospecific rabbit anti-human TTR antiserum
(Dako, Ely, Cambridge, UK), and calibrated with isolated
pure wild-type TTR (Scipac Ltd). Total 125I in whole blood
was measured in a Perkin Elmer 2470 Auto gamma counter
with results expressed as cpm mg21. Localization of tracer
to kidney, spleen and liver was also determined after wash-
ing the organs in PBS. Clearance half-lives were estimatedwith GraphPad PRISM 5.03 using a simple exponential
decay model.3. Results
3.1. Enhanced clearance of covalently crosslinked
transthyretin
Covalently crosslinked oligomers of TTRwere generated using
EDC and most of the product eluted in and just after the void
volume of the Superdex 200 column (figure 2a). The cross-
linked TTR retained the capacity to bind 125I-thyroxine and
Table 1. Oligomerization of TTR by bifunctional ligands.
ligand linker gel ﬁltration
Ia Pro5 no crosslinking
Ib
Ic
Id
Ie
If
Pro6
Pro7
Pro8
Pro9
Pro10
TTR eluted as a broad peak, consistent with crosslinking in the presence of excess ligand, followed by dissociation on the
column. Complexes were not stable to a second gel ﬁltration step
IIa
IIb
Pip3.CO.Pip3
Pip4.CO.Pip1
more stable crosslinking of pairs of native TTR tetramers than with group I ligands, however complexes still dissociated to
individual TTR tetramers on the column
IIc
IId
Pip4.CO.Pip4
Pip5.CO.Pip5
crosslinking of pairs of TTR molecules to form complexes stable on a repeat gel ﬁltration
IIe Pip5.CO.Pip2 TTR eluted as a broad peak, consistent with the formation of larger oligomers which dissociate on the column (ligand IIe
contained a modiﬁed short ether linkage between the head group and the polypiperidine)
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remained at the origin, well separated from native TTR, with
some lower molecular weight oligomers appearing as an
anodal smear (figure 2a, inset). The electrophoretic and gel
filtration data are both consistent with the generation of high-
mass oligomers of TTR by EDC treatment. EDC-125I-TTR was
cleared from the circulation in wild-type mice much more
rapidly than 125I-TTR. In previous studies, we have found the
plasma half-life of native 125I-human TTR in wild-type mice
to be mean (s.d.), 48.0 (17.6) min, n ¼ 7; here, it was 43.5 min
with clearance of only 5.5% in the first 5 min. In contrast,
39.4% of the EDC-125I-TTRwas cleared by 5 min, and clearance
of the remainder could not be curve fitted (figure 2b). When
organs were counted after clearance was complete, there was
over 10-foldmore radioactivity in the spleens of mice receiving
EDC-TTR than those given native control TTR (figure 2c).Ib
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Figure 3. (a) The A280 UV absorbance gel filtration profiles of native TTR
(dotted line) and TTR incubated with a fourfold excess of ligand Ie (Pro9,
solid line). The ligand has caused an increase in peak volume and a conco-
mitant decrease in retention volume consistent with the formation of a ligand
octamer complex followed by dissociation on the column. (b) The effect of
ligands on peak width is dose-dependent for all ligands except Ia (Pro5)
where no octamer formation has occurred.3.2. Preparation and effects of potential crosslinking
compounds
A range of potential TTR crosslinking agents were designed
from a selection of readily available building blocks that
allowed exploration of linker length and flexibility. They
were prepared by coupling the TTR-binding head group,
5-amino-2-(3,5-dichlorophenylamino)benzoic acid, to a variety
of rigid and non-rigid linkers based on polyproline (Pro) and
polypiperidine (Pip) functionalities (figure 1 and table 1). The
dichlorophenylaminobenzoic head group was chosen as it
had been previously reported by Purkey et al. [21] to be
avidly bound by TTR in plasma, and was the basis for the
development of our TTR superstabilizer, mds84 [16]. Group I
ligands contained linear chains of 5–10 proline residues
coupled at each end through C6 amides. Group II ligands
were polypiperidines linked through a central carbonyl
group and further coupled through either 3-aminopropanol
or 3-hydroxypropamide. Each ligand was efficiently bound
by TTR at the thyroxine binding site with IC50 values less
than 5 mM in the standard thyroxine displacement assay [16].
Gel filtration of native tetrameric TTR on Superdex 200
eluted with PBS yielded a major component eluting at
14.4+ 0.2 ml and with a peak width at half height of0.8 ml. There was also a minor peak, comprising about 5%
of the total protein, at Ve 12.7 ml (figure 3a), produced by
the naturally occurring dimerization of pairs of TTR tetra-
mers [22]. Overnight incubation of TTR with up to a
fourfold molar excess of the pentaproline ligand (Ia) had no
effect on the gel filtration profile of the protein, with the
main A280 component eluting at 14.5 ml with a peak width
of 0.8 ml; there was, however, a fourfold increase in the
A330/A280 UV absorbance ratio for the tetrameric complex
at the highest ligand concentration, demonstrating that the
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Figure 4. (a) Treatment of TTR with the polypiperidine ligand IIc generates an octameric complex which elutes on gel filtration with a retention volume of 12.8 ml
and is separated from native tetrameric TTR at 14.6 ml. (b) The octamer (fraction 12) is stable to a second step of gel filtration. (c) Mass spectrometric examination
of the complex of TTR with ligand IIc is consistent with the formation of a bis ligand octamer. Native apo TTR appears as the tetramer (T, charge states 11þ to
14þ, 56 500+ 50 Da). Addition of increasing levels of the ligand results in the dose dependent formation of an octameric species containing two ligands (O2,
charge states 17þ to 20þ, 115 715+ 50 Da). (d ) The TTR/IIc complex dissociates as the desolvation energy is increased (80, 100 and 120 V, top to bottom
panels). The holo octameric TTR complex with two ligands bound (17þ to 20þ, O2) dissociates to the octamer with one ligand (O1) and apo octamer (O) con-
firming stoichiometry of the TTR ligand complex formed. Release of monomers (M) also occurs under increasing desolvation energy. Mass spectra for the TTR/IId
complex are shown in the electronic supplementary material, S1.
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TTR with each of the remaining polyproline ligands (Ib–If,
Pro6–10) caused a dose-dependent broadening of the TTR
peak, with an increase in half-height peak width by up to
0.62 ml (figure 3b), together with a concomitant reduction
in TTR elution volume. This was consistent with formation
of crosslinked pairs of native tetrameric TTR molecules in
the presence of excess ligand and their subsequent dis-
sociation as free ligand was removed during gel filtration.
The largest effect on peak width and retention time was
observed with the Pro9 and Pro10 ligands, Ie and If. When
the main A280-absorbing fractions from these samples were
re-chromatographed on Superdex 200 each of the proteins
eluted in the native position and with native half-height
peak width (data not shown), showing that the complexes
had completely dissociated when all the free ligand was
removed by gel filtration. The formation of a complex of
two TTR molecules by the Pro9 containing ligand Ie wasconfirmed by sedimentation ultracentrifugation in the pres-
ence of excess ligand, with appearance of a new species at
5.2S compared with native tetrameric TTR alone at 3.9S.
The presence and composition of ligand crosslinked TTR
complexes was also investigated by nanoflow electrospray
mass spectrometry. Under low-energy conditions designed
for observation of non-covalent protein–protein interactions,
native TTR populated four charge states (11þ to 14þ) corre-
sponding to the expected tetrameric assembly (56 500+
50 Da). After incubationwith 0.5- to twofoldmolar equivalents
of group I ligands there was dose-dependent appearance of
TTR tetramers with one, and eventually two, bound ligand
molecules occupying the thyroxine binding sites. With ligands
Ib to Ie, low-intensity peaks (less than 10%) assigned to pairs of
TTR tetramers with one to three bound ligand molecules
were observed confirming the interpretation of the gel filtration
findings. As these ligands did not generate stable octameric
complexes with TTR, they were not studied further.
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Figure 6. (a) The complex formed between ligand IIe and TTR contained an
appreciable amount of a larger molecular mass species chromatographing on
gel filtration as a dodecamer at approximately 11.0 ml (solid line) and sep-
arated from native TTR (dotted line). The complex was unstable, regenerating
the tetramer (at 14.7 ml) together with a small amount of octamer (12.8 ml)
on a second step of gel filtration (inset). (b) Nanoflow electrospray mass spec-
trum of TTR in the presence of 1 molar equivalent of ligand IIe. Under soft
desolvation conditions, several charge state series are observed corresponding
to apo tetrameric TTR (11þ to 13þ, T), holo octameric TTR with one ligand
bound (17þ to 19þ, O1) and holo dodecameric TTR with two or three
ligands bound (22þ to 24þ, D2/3). Higher oligomeric species are also
observed above 8000 m/z. (c) Tandem mass spectrum of the 19þ charge
state of O1 shows the release of individual monomeric TTR (M) and the
formation of ‘stripped complex’ H1 corresponding to heptameric TTR with
one ligand bound. (d ) Tandem mass spectrum of the 24þ charge state
of D2/3 shows the release of individual monomeric TTR (M) and the formation
of ‘stripped complex’ U2 corresponding to undecameric TTR with two ligands
bound. Ion charges are shown for the most intense species in each ion series.
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(Pip4.CO.Pip1), had effects similar to the group I ligands.
There was some crosslinking that dissociated on gel filtration
although the maximum peak widths produced by IIa and IIb,
1.6 and 2.1 ml, respectively, were considerably greater than
obtained with any of the group I polyproline ligands
suggesting that the polypiperidine complexes were more
stable. Again, the complexes dissociated back to tetramer
when subjected to a second gel filtration.
In contrast, ligands IIc (Pip4.CO.Pip4) and IId (Pip5.CO.Pip5)
produced stable crosslinking with the complex eluting at
12.8 ml (figure 4a). Complex formation was dose-dependent,
with over 90% of the TTR incorporated following 18 h incu-
bation in the presence of a twofold molar excess of ligand,
and these assemblies were stable to a second gel filtration step
(figure 4b). Mass spectrometric analysis confirmed that treat-
ment of TTR with ligands IIc or IId dose-dependently
produced substantial amounts of a higher mass complex.
Surprisingly, the molecular mass of approximately 116 000 Da
was consistent with two TTR tetramers crosslinked by two
ligand molecules (figure 4c) and this stoichiometry was con-
firmed under dissociating MS conditions (figure 4d). In
contrast with the reversibly bound group I and group II ligands,
no species were seen at normal operating cone voltages with
either ligand bound by native tetrameric TTR molecules, or
one or three ligand molecules bound by pairs of tetramers.
3.3. In vivo clearance studies
Native TTR was spiked with a trace of 125I-TTR and then incu-
bated with a twofold excess of ligand IIc (Pip4.CO.Pip4).
Although the A280 gel filtration profile confirmed more than
95% crosslinking of TTR protein only 60% of the 125I radiolabelwas in the complex, indicating that oxidative radioiodination
of TTR had partially inactivated the thyroxine binding sites.
The tracer was thus not ideal for monitoring in vivo clearance
of the TTR–ligand complex. Nevertheless, 200 mg of the pre-
formed TTR–IIc complex containing 125I-TTR was injected
intravenously into mice, and its clearance from the plasma
was quantified both by radioactive counting and by specific
immunoassay for human TTR. There was no change in the
rate of clearance of the complex compared with control; the
estimated half-lives were 82.2 and 68.7 min, respectively,
(b)(a)
Figure 7. Models for the proposed TTR/Ie octameric complex (a) and the bracelet structure for TTR/IIc (b). The pictures were made using PyMOL Molecular Graphics
System, version 0.99, Schro¨dinger, LLC.
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for clearance of native TTR in TTR knockout mice (mean (s.d.),
73.1 (37.2) min, n ¼ 8; figure 5a). The 60 min serum samples
from animals that had received control and ligand-treated
TTR were fractionated by gel filtration and analysed for radio-
activity. Native size, tetrameric 125I-TTR was present in the
control serum but serum from the mice given the ligand-
treated TTR contained a mixture of tetrameric TTR and
dimers thereof (figure 5b). Because 40% of the radiolabelled
125I-TTR was not capable of ligand binding, these results
demonstrate that the TTR–ligand complex is stable in vivo
but is not cleared at an accelerated rate.
A number of other ligands with polypiperidine linkers
were also synthesized, one of which, IIe, formed a higher
molecular mass complex with TTR, possibly a dodecamer,
eluting on gel filtration at approximately 11.0 ml (figure 6a).
The complex was not stable in the absence of excess ligand,
breaking down to yield the tetramer on further gel filtration.
Spectrophotometric analysis of the relative absorbance at
330 nm for ligand and 280 nm for TTR protein demonstrated
that the high-mass complexes did contain the ligand. Further-
more, mass spectrometric analysis identified species with two
tetrameric TTR molecules and one or two ligand molecules,
three TTRs with two or three ligands, and some higher
mass species (figure 6b), presumably representing daisy
chains of alternating TTR tetramers, each with their two
known binding sites, crosslinked by bifunctional ligands.
The assignments were confirmed by tandem MS analysis of
the octamer containing one ligand which shows the release
of individual monomeric TTR and the formation of a
‘stripped complex’ of heptameric TTR with one ligand
bound. Similar analysis of dodecameric TTR with two
ligands bound also shows release of individual monomeric
TTR together with the formation of stripped undecameric
TTR containing two ligands (figure 6c,d).4. Discussion
The development of the hexanoyl bis(D-proline) drug, (R)-1-[6-
[(R)-2-carboxy-pyrrolidin-1-yl]-6-oxo-hexanoyl]pyrrolidine-2-
carboxylic acid (CPHPC), which rapidly and almost comple-
tely depletes its target protein, SAP, from the plasma for as
long as the drug is administered, identified a novel pharmaco-
logical mechanism [12,13]. The essential feature is prompt
hepatic clearance of the stable complex formed by two SAP
molecules crosslinked by bifunctional ligand molecules. We
speculated that this mechanism might operate with other
pathogenic plasma protein targets if it was possible to design
a suitably specific and avidly bound crosslinking ligand.
Each native homotetrameric TTR molecule has two identicalthyroxine binding pockets and the work of Purkey et al. [21]
had identified (3,5-dichlorophenylamino)benzoic acid as a
specific high affinity ligand bound in this site by TTR within
the milieu of whole serum. It is thus a suitable starting point
for construction of the required crosslinking structure. In our
original effort to create such a compound, we attached the
ligand head groups in an orientation that serendipitously
enabled the molecule to enter one thyroxine binding site and
then traverse the channel through the centre of the TTR mol-
ecule, so that both binding sites were occupied with the
linker threaded internally through the protein [16]. Here, we
therefore attached the head groups in the opposite orientation,
to avoid such threading and to enable crosslinking of different
TTR molecules to take place, and used linkers with lengths of
20–50 A˚, sufficient, based on our modelling studies, to reach
between two adjacent TTR tetramers (figure 7).
Our approach, of enhancing clearance of the amyloid pre-
cursor, differs from the TTR stabilization method which
underlies the mode of action of the drugs currently in clinical
use, tafamidis (Vyndaqel) and diflunisal [23–26]. While some
degree of stabilization of the native TTR tetramer may also be
conferred by our bifunctional ligands, the major beneficial
effect would arise through depletion of plasma TTR rather
than stabilization of the native tetramer. This may be impor-
tant since recent work from our laboratory indicates that a
mechano-enzymatic mechanism plays a prominent role in
TTR amyloid fibrillogenesis [27] and that TTR tetramer stabil-
ization alone may be insufficient to block amyloid formation
if it does not also protect against the key proteolytic cleavage.
The rapid plasma clearance of the heterogeneous, mostly
high mass, aggregates of TTR produced by covalent cross-
linking with EDC is unsurprising and entirely as expected,
because even trivial structural alteration of many plasma pro-
teins, as for example after oxidative trace radioiodination or
other inadvertent denaturation during isolation, has long
been known to promote accelerated clearance by the liver
and spleen. The major uptake of chemically aggregated
TTR in the spleen is nonetheless of interest in view of the pro-
pensity of TTR and other types of amyloid to deposit in the
spleen but we have no evidence that our model has any
pathophysiological relevance in this context. We used EDC-
TTR only to confirm that TTR aggregates would be cleared
from the circulation more rapidly than single native TTR mol-
ecules and to show that we could detect the difference, before
going on to test the effect of our crosslinking ligands.
Rigid polyproline chains, Pro5–Pro10 in compounds Ia–If
respectively, were initially used as linkers, and other than
Ia (Pro5) each ligand was capable of crosslinking TTR consist-
ent with a minimum inter-tetramer distance of approximately
30 A˚ in the TTR–ligand–TTR complex (figure 7a). However,
the complexes were unstable in the absence of excess free
rsob.royalsocietypublishing.org
Open
Biol.5:150105
8
 on October 7, 2015http://rsob.royalsocietypublishing.org/Downloaded from ligand. Nevertheless, mass spectrometric analysis of mixtures
of TTR with excess ligands identified complexes of TTR with
one or two ligand molecules bound and a low abundance of
pairs of TTR molecules with one, two and three bound
ligand molecules. Thus, if the stability problem could be
overcome, both pairs and higher oligomers of TTR could
potentially be produced.
In contrast to the rigid polyproline linker compounds, two
of the compounds with flexible polypiperidine linkers, IIc and
IId, produced dose-dependent stable crosslinking of pairs of
TTR molecules. These complexes each contained two ligand
molecules consistent with a bracelet structure in which the lin-
kers encircle the globular TTR protein assembly (figure 7b).
With a small rotation of the TTR tetramers, the approximately
40 A˚ length of the polypiperidine linker in IIc is compatible
with the head groups being engaged in the binding pockets,
whereas the linker chain emerges through a furrow normal to
the TTR head group axis. Acidic residues flanking the furrow
could additionally stabilize the complex in comparison with
the ‘daisy chain’ crosslinking configuration provided by the
rigid linear polyPro compounds.
Although the TTR–IIc complex was stable in vivo as well
as in vitro, it was not cleared from the circulation at an accel-
erated rate. This may reflect the fact that a substantial
proportion of TTR normally circulates in a stable complex
with retinol binding protein and the modestly increased
size of the TTR–IIc complex is insufficient to trigger
enhanced clearance. The modelled radius of gyration is
only 29.96 A˚ compared with 22.67 A˚ for the native TTR tetra-
mer. Unlike SAP, no simple crosslinking of pairs of TTRmolecules will lead to TTR depletion from the plasma.
Larger oligomers, as produced by covalent crosslinking
with EDC, were swiftly cleared, and in theory, therefore,
higher-order oligomers in the daisy chain configuration pro-
duced by rigid linker ligands should be effectively cleared.
Here, we observed the complexes of three TTR molecules
with compound IIe, but potent ligands of this type will
require head groups that are specifically bound by TTR
with much greater affinity than any we have yet identified
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